vs
Lantheus Holdings, Inc.（LNTH）とRapid7, Inc.（RPD）の財務データ比較。上の社名をクリックして会社を切り替えられます
Lantheus Holdings, Inc.の直近四半期売上が大きい（$406.8M vs $217.4M、Rapid7, Inc.の約1.9倍）。Lantheus Holdings, Inc.の純利益率が高く（13.3% vs 1.4%、差は11.9%）。Lantheus Holdings, Inc.の前年同期比売上増加率が高い（4.0% vs 0.5%）。Lantheus Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$81.4M vs $36.4M）。過去8四半期でLantheus Holdings, Inc.の売上複合成長率が高い（4.9% vs 3.0%）
ランティウス・ホールディングスはグローバルな医療企業で、革新的な診断用造影剤や関連ソリューションの開発・製造・販売を事業の核としています。製品は腫瘍学、循環器学、泌尿器学などの分野に対応し、北米を中心に世界の主要市場で事業を展開しています。
Rapid7社は世界的に有名なサイバーセキュリティ企業で、脆弱性管理、脅威検知・対応、クラウドセキュリティ、セキュリティ分析などの総合的なソリューションを提供しています。テクノロジー、医療、金融、製造業などの各業種の企業や公共部門を顧客とし、サイバー脅威への効率的な対応を支援します。
LNTH vs RPD — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $406.8M | $217.4M |
| 純利益 | $54.1M | $3.1M |
| 粗利率 | 59.2% | 68.9% |
| 営業利益率 | 19.0% | 1.0% |
| 純利益率 | 13.3% | 1.4% |
| 売上前年比 | 4.0% | 0.5% |
| 純利益前年比 | 558.8% | 44.1% |
| EPS（希薄化後） | $0.86 | $0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $406.8M | $217.4M | ||
| Q3 25 | $384.0M | $218.0M | ||
| Q2 25 | $378.0M | $214.2M | ||
| Q1 25 | $372.8M | $210.3M | ||
| Q4 24 | $391.1M | $216.3M | ||
| Q3 24 | $378.7M | $214.7M | ||
| Q2 24 | $394.1M | $208.0M | ||
| Q1 24 | $370.0M | $205.1M |
| Q4 25 | $54.1M | $3.1M | ||
| Q3 25 | $27.8M | $9.8M | ||
| Q2 25 | $78.8M | $8.3M | ||
| Q1 25 | $72.9M | $2.1M | ||
| Q4 24 | $-11.8M | $2.2M | ||
| Q3 24 | $131.1M | $15.4M | ||
| Q2 24 | $62.1M | $6.5M | ||
| Q1 24 | $131.1M | $1.4M |
| Q4 25 | 59.2% | 68.9% | ||
| Q3 25 | 57.9% | 70.2% | ||
| Q2 25 | 63.8% | 70.6% | ||
| Q1 25 | 63.8% | 71.7% | ||
| Q4 24 | 63.5% | 69.5% | ||
| Q3 24 | 63.9% | 70.6% | ||
| Q2 24 | 64.9% | 70.7% | ||
| Q1 24 | 65.4% | 70.3% |
| Q4 25 | 19.0% | 1.0% | ||
| Q3 25 | 11.4% | 2.7% | ||
| Q2 25 | 23.3% | 1.6% | ||
| Q1 25 | 27.4% | -0.0% | ||
| Q4 24 | 29.1% | 3.4% | ||
| Q3 24 | 35.3% | 6.0% | ||
| Q2 24 | 26.1% | 2.5% | ||
| Q1 24 | 28.8% | 4.7% |
| Q4 25 | 13.3% | 1.4% | ||
| Q3 25 | 7.2% | 4.5% | ||
| Q2 25 | 20.8% | 3.9% | ||
| Q1 25 | 19.6% | 1.0% | ||
| Q4 24 | -3.0% | 1.0% | ||
| Q3 24 | 34.6% | 7.2% | ||
| Q2 24 | 15.8% | 3.1% | ||
| Q1 24 | 35.4% | 0.7% |
| Q4 25 | $0.86 | $0.05 | ||
| Q3 25 | $0.41 | $0.15 | ||
| Q2 25 | $1.12 | $0.13 | ||
| Q1 25 | $1.02 | $0.03 | ||
| Q4 24 | $-0.18 | $0.08 | ||
| Q3 24 | $1.79 | $0.21 | ||
| Q2 24 | $0.88 | $0.09 | ||
| Q1 24 | $1.87 | $0.02 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $359.1M | $474.7M |
| 総負債低いほど良い | $568.7M | — |
| 株主資本純資産 | $1.1B | $154.7M |
| 総資産 | $2.2B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | 0.52× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $359.1M | $474.7M | ||
| Q3 25 | $382.0M | $407.1M | ||
| Q2 25 | $695.6M | $511.7M | ||
| Q1 25 | $938.5M | $493.5M | ||
| Q4 24 | $912.8M | $521.7M | ||
| Q3 24 | $866.4M | $443.7M | ||
| Q2 24 | $757.0M | $442.6M | ||
| Q1 24 | $718.3M | $411.7M |
| Q4 25 | $568.7M | — | ||
| Q3 25 | $567.9M | — | ||
| Q2 25 | $566.8M | — | ||
| Q1 25 | $566.1M | — | ||
| Q4 24 | $565.3M | — | ||
| Q3 24 | $613.0K | — | ||
| Q2 24 | $563.2M | — | ||
| Q1 24 | $562.5M | — |
| Q4 25 | $1.1B | $154.7M | ||
| Q3 25 | $1.1B | $127.2M | ||
| Q2 25 | $1.2B | $90.4M | ||
| Q1 25 | $1.2B | $52.7M | ||
| Q4 24 | $1.1B | $17.7M | ||
| Q3 24 | $1.2B | $-5.1M | ||
| Q2 24 | $1.0B | $-52.6M | ||
| Q1 24 | $945.5M | $-86.4M |
| Q4 25 | $2.2B | $1.7B | ||
| Q3 25 | $2.3B | $1.7B | ||
| Q2 25 | $2.1B | $1.6B | ||
| Q1 25 | $2.1B | $1.6B | ||
| Q4 24 | $2.0B | $1.7B | ||
| Q3 24 | $2.0B | $1.6B | ||
| Q2 24 | $1.9B | $1.5B | ||
| Q1 24 | $1.8B | $1.5B |
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | 0.59× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $90.2M | $37.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $81.4M | $36.4M |
| FCFマージンFCF / 売上 | 20.0% | 16.8% |
| 設備投資強度設備投資 / 売上 | 2.2% | 0.5% |
| キャッシュ転換率営業CF / 純利益 | 1.67× | 12.01× |
| 直近12ヶ月FCF直近4四半期 | $354.1M | $146.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $90.2M | $37.6M | ||
| Q3 25 | $105.3M | $39.0M | ||
| Q2 25 | $87.1M | $47.5M | ||
| Q1 25 | $107.6M | $29.8M | ||
| Q4 24 | $157.7M | $63.8M | ||
| Q3 24 | $175.1M | $44.0M | ||
| Q2 24 | $84.7M | $32.9M | ||
| Q1 24 | $127.2M | $31.1M |
| Q4 25 | $81.4M | $36.4M | ||
| Q3 25 | $94.7M | $34.8M | ||
| Q2 25 | $79.1M | $46.6M | ||
| Q1 25 | $98.8M | $28.4M | ||
| Q4 24 | $141.4M | $62.6M | ||
| Q3 24 | $159.3M | $42.6M | ||
| Q2 24 | $73.5M | $32.6M | ||
| Q1 24 | $119.0M | $30.4M |
| Q4 25 | 20.0% | 16.8% | ||
| Q3 25 | 24.7% | 16.0% | ||
| Q2 25 | 20.9% | 21.8% | ||
| Q1 25 | 26.5% | 13.5% | ||
| Q4 24 | 36.1% | 28.9% | ||
| Q3 24 | 42.0% | 19.9% | ||
| Q2 24 | 18.7% | 15.7% | ||
| Q1 24 | 32.2% | 14.8% |
| Q4 25 | 2.2% | 0.5% | ||
| Q3 25 | 2.8% | 1.9% | ||
| Q2 25 | 2.1% | 0.4% | ||
| Q1 25 | 2.3% | 0.6% | ||
| Q4 24 | 4.2% | 0.5% | ||
| Q3 24 | 4.2% | 0.6% | ||
| Q2 24 | 2.8% | 0.1% | ||
| Q1 24 | 2.2% | 0.3% |
| Q4 25 | 1.67× | 12.01× | ||
| Q3 25 | 3.79× | 3.97× | ||
| Q2 25 | 1.11× | 5.70× | ||
| Q1 25 | 1.47× | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | 1.34× | 2.85× | ||
| Q2 24 | 1.36× | 5.03× | ||
| Q1 24 | 0.97× | 22.10× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
